Pulmonary arterial hypertension (PAH) is characterized by pulmonary vascular remodeling leading to right ventricular hypertrophy (RVH) and failure. Peroxisome proliferator-activated receptor γ (PPARγ)， a member of nuclear receptors， has been proved to ameliorate PAH. However， its effect on PAH-induced right ventricular failure (RVF) remains unknown. Therefore， we investigated the therapeutic potential of PPARγ in preventing monocrotaline (MCT)-induced RV dysfunction. The PAH model was induced by MCT administration. Male rats were administered with MCT to develop PAH and RVF formed by approximately day 30. Significant increase in RV area， RVAW resulted in an ascending RV index. However， the LV function including EF， FS， and LVID did not change significantly. PPARγ agonist prevented PAH-induced RVF by preserving RV index and preventing RVH. PPARγ's beneficial effects seem to result from various factors， including anti-apoptosis， preservation RV index， reversal of inflammation， improvement of glucolipid metabolism， reduction of ROS. In a word， PPARγ agonist prevents the development of RVF.